avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2021-12-2-113-122avk-1404Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESСовременное представление о тяжелой бронхиальной астмеModern Understanding of Severe Bronchial Asthmahttps://orcid.org/0000-0001-6896-877XКрапошинаА. Ю.KraposhinaA. Yu.

Красноярск

Krasnoyarsk

https://orcid.org/0000-0002-9377-5213СобкоЕ. А.SobkoE. A.

Красноярск

Krasnoyarsk

https://orcid.org/0000-0001-8982-5292ДемкоИ. В.DemkoI. V.

Красноярск

Krasnoyarsk

https://orcid.org/0000-0002-6649-8900КацерА. Б.KatserA. B.

Красноярск

Krasnoyarsk

https://orcid.org/0000-0001-7999-4113КазмерчукО. В.KazmerchukO. V.

Красноярск

Krasnoyarsk

https://orcid.org/0000-0002-9937-1025АбрамовЮ. И.AbramovYu. I.

Красноярск

Krasnoyarsk

Федеральное государственное бюджетное образовательное учреждение высшего образования «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской Федерации; Краевое государственное бюджетное учреждение здравоохранения «Краевая клиническая больница»РоссияProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Regional Government-Owned Publicly Funded Healthcare Institution “Regional Clinical Hospital”Russian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской ФедерацииРоссияProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityRussian Federation202230032022122113122Copyright © Крапошина А.Ю., Собко Е.А., Демко И.В., Кацер А.Б., Казмерчук О.В., Абрамов Ю.И., 20222022Крапошина А.Ю., Собко Е.А., Демко И.В., Кацер А.Б., Казмерчук О.В., Абрамов Ю.И.Kraposhina A.Y., Sobko E.A., Demko I.V., Katser A.B., Kazmerchuk O.V., Abramov Y.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/1404

В обзоре приведены современные данные о тяжелой бронхиальной астме. Частые обострения астмы значимо снижают качество жизни пациентов, становятся причиной потери трудоспособности, инвалидизации и летального исхода. Гетерогенность тяжелой бронхиальной астмы укладывается в понятия фенотипа и эндотипа, идентификация которых в клинической практике имеет ограничения, но является необходимой для персонализированной терапии. Анализ литературы, отражающей опыт в ведении данных пациентов, необходим для формирования целостных представлений о тяжелой бронхиальной астме и разработки путей оптимизации терапии.

The review provides data on severe bronchial asthma. Frequent exacerbations of asthma significantly reduce the quality of life of patients, cause disability, disability and death. The heterogeneity of severe bronchial asthma fits into the concepts of phenotype and endotype, the identification of which in clinical practice has limitations, but is necessary for personalized therapy. Analysis of the literature reflecting experience in patient data management is needed to form holistic perceptions of severe bronchial asthma and develop ways to optimize therapy.

фенотипэндотиптяжелая бронхиальная астмаphenotypeendotypesevere bronchial asthmaReferencesGlobal Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Members of GINA Committees. 2020; 1-211. [Electronic resource]. URL: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Members of GINA Committees. 2020; 1-211. [Electronic resource]. URL: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.Авдеев С.Н., Ненашева Н.М., Жуденков К.В. и др. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации. Пульмонология. 2018; 28(3): 341-358. doi: 10.18093/0869-0189-2018-28-3-341-358Avdeev S.N., Nenasheva N.M., Zhudenkov K.V. et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Russian Pulmonology. 2018; 28(3): 341-358. doi: 10.18093/0869-0189-2018-28-3-341-358 [In Russian].Демко И.В., Собко Е.А., Чубарова С.В. и др. Особенности системного воспаления, функции внешнего дыхания и морфологической структуры слизистой оболочки бронхов при тяжелой бронхиальной астме. Сибирское медицинское обозрение. 2014; 5: 47-52.Demko I.V., Sobko E.A., Chubarova S.V. et al. Features of the systemic inflammation, external respiration functions and morphological structure of the bronchial mucous membrane in severe bronchial asthma. Sibirskoe meditsinskoe obozrenie. 2014; 5: 47-52. [In Russian].Белевский А.С., Зайцев А.А. Фармакоэкономические аспекты терапии бронхиальной астмы. Медицинский совет. 2018;15: 60-68. doi:10.21518/2079-701X-2018-15-60-68Belevsky A.S., Zaitsev A.A. Pharmacoeconomic aspects of bronchial asthma therapy: real clinical practice. Meditsinskiy sovet = Medical Council. 2018; (15): 60-68. doi: 10.21518/2079-701X-2018-15-60-68 [In Russian].Nagase H. Severe asthma in Japan. Allergology International. 2019; 68(2): 167-171. doi:10.1016/j.alit.2019.02.004Nagase H. Severe asthma in Japan. Allergology International. 2019; 68(2): 167-171. doi:10.1016/j.alit.2019.02.004O’Toole J., Mikulic L., Kaminsky D.A. Epidemiology and pulmonary physiology of severe asthma. Immunology and Allergy Clinics of North America. 2016; 36(3): 425-438. doi: 10.1016/j.iac.2016.03.001O’Toole J., Mikulic L., Kaminsky D.A. Epidemiology and pulmonary physiology of severe asthma. Immunology and Allergy Clinics of North America. 2016; 36(3): 425-438. doi: 10.1016/j.iac.2016.03.001Бродская О.Н. Бронхиальная астма с частыми обострениями: факторы риска и меры профилактики. Практическая пульмонология. 2016; 3: 11-18.Brodskaya O.N. Bronchial asthma with frequent exacerbations: risk factors and prevention measures. Prakticheskaya pul’monologiya. 2016; 3: 11-18. [In Russian].Zein J.G., Dweik R.A., Comhair S.A. et al. Asthma is more severe in older adults. PLoS One. 2015; 10(7): e0133490. doi: 10.1371/journal. pone.0133490Zein J.G., Dweik R.A., Comhair S.A. et al. Asthma is more severe in older adults. PLoS One. 2015; 10(7): e0133490. doi: 10.1371/journal. pone.0133490Ненашева Н.М. Это трудное слово «комплайнс», или Как можно повысить приверженность лечению при бронхиальной астме. Астма и аллергия. 2013; 2: 15-19.Nenasheva NM. This is a difficult word for «compliance», or How one can increase adherence to treatment for bronchial asthma. Asthma and allergy. 2013:2:15-19. [In Russian].Hekking P.W., Wener R.R., Amelink M. et al. The prevalence of severe refractory asthma. Journal of Allergy and Clinical Immunology. 2015; 135(4): 896-902. doi: 10.1016/j.jaci.2014.08.042Hekking P.W., Wener R.R., Amelink M. et al. The prevalence of severe refractory asthma. Journal of Allergy and Clinical Immunology. 2015; 135(4): 896-902. doi: 10.1016/j.jaci.2014.08.042von Bülow A., Backer V., Bodtger U. et al. Differentiation of adult severe asthma from difficult-to-treat asthma — Outcomes of a systematic assessment protocol. Respiratory Medicine. 2018; 145: 41-47. doi: 10.1016/j.rmed.2018.10.020von Bülow A., Backer V., Bodtger U. et al. Differentiation of adult severe asthma from difficult-to-treat asthma — Outcomes of a systematic assessment protocol. Respiratory Medicine. 2018; 145: 41-47. doi: 10.1016/j.rmed.2018.10.020van der Meer A.N., Pasma H., Kempenaar-Okkema W. et al. A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use. European Respiratory Journal. 2016; 48(3): 726-733. doi: 10.1183/13993003.00220-2016van der Meer A.N., Pasma H., Kempenaar-Okkema W. et al. A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use. European Respiratory Journal. 2016; 48(3): 726-733. doi: 10.1183/13993003.00220-2016Verhamme K.M.C., Lucet C., Van Meerhaeghe A. et al. Real- life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. European Journal of Operational Research. 2019; 5: 00253-2018. doi: 10.1183/23120541.00253-2018Verhamme K.M.C., Lucet C., Van Meerhaeghe A. et al. Real- life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. European Journal of Operational Research. 2019; 5: 00253-2018. doi: 10.1183/23120541.00253-2018Chung K.F., Wenzel S.E., Brozek J.L. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal. 2014; 43(2): 343-373. doi: 10.1183/09031936.00202013Chung K.F., Wenzel S.E., Brozek J.L. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal. 2014; 43(2): 343-373. doi: 10.1183/09031936.00202013Wark P.A.B, Hew M., Maltby S. et al. Diagnosis and investigation in the severe asthma clinic. Expert review of respiratory medicine. 2016; 10(5): 491-503. doi: 10.1586/17476348.2016.1165096Wark P.A.B, Hew M., Maltby S. et al. Diagnosis and investigation in the severe asthma clinic. Expert review of respiratory medicine. 2016; 10(5): 491-503. doi: 10.1586/17476348.2016.1165096Majellano E.C., Clark V.L., Winter N.A. et al. Approaches to the assessment of severe asthma: barriers and strategies. Journal of Asthma and Allergy. 2019; 12: 235-251 doi: 10.2147/JAA.S178927Majellano E.C., Clark V.L., Winter N.A. et al. Approaches to the assessment of severe asthma: barriers and strategies. Journal of Asthma and Allergy. 2019; 12: 235-251 doi: 10.2147/JAA.S178927Hashimoto S., Bel E.H. Current treatment of severe asthma. Clinical and Experimental Allergy. 2012; 42(5): 693-705. doi: 10.1111/j.1365- 2222.2011.03936.xHashimoto S., Bel E.H. Current treatment of severe asthma. Clinical and Experimental Allergy. 2012; 42(5): 693-705. doi: 10.1111/j.1365- 2222.2011.03936.xJeong J.S., Lee Y.C. Basics of Severe Asthma in Clinical Practice. In: Severe Asthma. Springer, Singapore. 2018: 3-12. doi: 10.1007/978- 981-10-1998-2_1Jeong J.S., Lee Y.C. Basics of Severe Asthma in Clinical Practice. In: Severe Asthma. Springer, Singapore. 2018: 3-12. doi: 10.1007/978- 981-10-1998-2_1Kang H-R., Song H.J., Nam J.H. et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population- based observational study in South Korea. BMJ Open. 2018; 8(3): e020825. doi: 10.1136/bmjopen-2017-020825Kang H-R., Song H.J., Nam J.H. et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population- based observational study in South Korea. BMJ Open. 2018; 8(3): e020825. doi: 10.1136/bmjopen-2017-020825McDonald V.M., Maltby S., Reddel H.K. et al. Severe asthma: Current management, targeted therapies and future directions-A roundtable report. Respirology. 2017; 22(1): 53-60. doi: 10.1111/resp.12957McDonald V.M., Maltby S., Reddel H.K. et al. Severe asthma: Current management, targeted therapies and future directions-A roundtable report. Respirology. 2017; 22(1): 53-60. doi: 10.1111/resp.12957Menzies-Gow A., Chiu G. Perceptions of asthma control in the United Kingdom: a cross-sectional study comparing patient and healthcare professionals’ perceptions of asthma control with validated ACT scores. NPJ Primary Care Respiratory Medicine. 2017; 27(1): 48. doi: 10.1038/s41533-017-0050-xMenzies-Gow A., Chiu G. Perceptions of asthma control in the United Kingdom: a cross-sectional study comparing patient and healthcare professionals’ perceptions of asthma control with validated ACT scores. NPJ Primary Care Respiratory Medicine. 2017; 27(1): 48. doi: 10.1038/s41533-017-0050-xBurke H., Davis J., Evans S. et al. A multidisciplinary team case management approach reduces the burden of frequent asthma admissions. European Journal of Operational Research. 2016; 2(3): 00039-2016. doi: 10.1183/23120541.00039-2016Burke H., Davis J., Evans S. et al. A multidisciplinary team case management approach reduces the burden of frequent asthma admissions. European Journal of Operational Research. 2016; 2(3): 00039-2016. doi: 10.1183/23120541.00039-2016Hedenrud T., Jakobsson A., Malla H.E., et al. «I did not know it was so important to take it the whole time» — self-reported barriers to medical treatment among individuals with asthma. BMC Pulmonary Medicine. 2019; 19: 175. doi: 10.1186/s12890-019-0934-3Hedenrud T., Jakobsson A., Malla H.E., et al. «I did not know it was so important to take it the whole time» — self-reported barriers to medical treatment among individuals with asthma. BMC Pulmonary Medicine. 2019; 19: 175. doi: 10.1186/s12890-019-0934-3Архипов В.В., Лазарева Н.Б. Принципы адекватного выполнения ингаляции. Практическая пульмонология. 2018; 3: 66-74.Gregoriano C., Dieterle T., Breitenstein A. et al. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial. Respiratory Research. 2018; 19(1): 237. doi: 10.1186/s12931-018-0936-3Gregoriano C., Dieterle T., Breitenstein A. et al. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial. Respiratory Research. 2018; 19(1): 237. doi: 10.1186/s12931-018-0936-3Lavorini F., Usmani O. Correct inhalation technique is critical in achieving good asthma control. Primary Care Respiratory Journal. 2013; 22: 385-386. doi: 10.4104/pcrj.2013.00097Lavorini F., Usmani O. Correct inhalation technique is critical in achieving good asthma control. Primary Care Respiratory Journal. 2013; 22: 385-386. doi: 10.4104/pcrj.2013.00097Jahedi L., Downie S.R., Saini B. et al. Inhaler Technique in Asthma: How Does It Relate to Patients’ Preferences and Attitudes Toward Their Inhalers? Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2017; 30(1): 42-52. doi: 10.1089/jamp.2016.1287Jahedi L., Downie S.R., Saini B. et al. Inhaler Technique in Asthma: How Does It Relate to Patients’ Preferences and Attitudes Toward Their Inhalers? Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2017; 30(1): 42-52. doi: 10.1089/jamp.2016.1287Asano K., Izuhara K. What we know, do not know, and should know about severe asthma. Allergology International. 2019; 68(2): 133-134. doi: 10.1016/j.alit.2019.03.002Asano K., Izuhara K. What we know, do not know, and should know about severe asthma. Allergology International. 2019; 68(2): 133-134. doi: 10.1016/j.alit.2019.03.002Nenasheva NM. Phenotypes and choice of therapy. Prakticheskaya pul’monologiya. 2014; 2: 2-11. [In Russian].Ненашева Н.М. Фенотипы и выбор терапии. Практическая пульмонология. 2014; 2: 2-11.Clinical guidelines. Bronchial asthma. Ministry of Health of the Russian Federation. 2021; 1-85. [Electronic resource]. URL: http://disuria.ru/_ld/10/1037_kr21J45J46MZ.pdf (date accessed 23/06/2021). [In Russian]Клинические рекомендации. Бронхиальная астма. Министерство здравоохранения Российской Федерации. 2021; 1–85. [Электронный ресурс]. URL: http://disuria.ru/_ld/10/1037_kr21J45J46MZ.pdf (дата обращения: 23.06.2021).Sergeeva G.R., Emelyanov A.V., Korovina O.V. et al. Severe asthma: Characteristics of patients in clinical practice. Terapevticheskii arkhiv. 2015; 87(12): 26-31. [In Russian].Сергеева Г.Р., Емельянов А.В., Коровина О.В. и др. Тяжелая бронхиальная астма: характеристика пациентов в клинической практике. Терапевтический архив. 2015; 87(12): 26-31.Nenasheva N.M., Belevskiy A.S., Fassahov R.S. et al. Asthma phenotypes difficult to treat: the possibility to achive a control. Russian Journal of Allergy. 2016; 4-5:43-54. [In Russian].Ненашева Н.М., Белевский А.С., Фассахов Р.С. и др. Фенотипы трудной для терапии бронхиальной астмы: возможности достижения контроля. Российский аллергологический журнал. 2016; 4-5: 43-54.Kämpe M., Vosough M, Malinovschi A. et al. Upper airway and skin symptoms in allergic and non-allergic asthma: results from the Swedish GA2LEN study. Journal of Asthma. 2018; 55(3): 275-283. doi: 10.1080/02770903.2017.1326132Kämpe M., Vosough M, Malinovschi A. et al. Upper airway and skin symptoms in allergic and non-allergic asthma: results from the Swedish GA2LEN study. Journal of Asthma. 2018; 55(3): 275-283. doi: 10.1080/02770903.2017.1326132Hirano T., Matsunaga K. Late-onset asthma: current perspectives. Journal of Asthma and Allergy. 2018 Feb 9; 11:19-27. Doi: 10.2147/JAA.S125948Hirano T., Matsunaga K. Late-onset asthma: current perspectives. Journal of Asthma and Allergy. 2018 Feb 9; 11:19-27. Doi: 10.2147/JAA.S125948Tan D.J., Walters E.H., Perret J.L. et al. Clinical and functional differences between early-onset and late-onset adult asthma: a population-based Tasmanian Longitudinal Health Study. Thorax. 2016; 71(11): 981–987. doi: 10.1136/thoraxjnl-2015-208183Tan D.J., Walters E.H., Perret J.L. et al. Clinical and functional differences between early-onset and late-onset adult asthma: a population-based Tasmanian Longitudinal Health Study. Thorax. 2016; 71(11): 981–987. doi: 10.1136/thoraxjnl-2015-208183Konstantellou E., Papaioannou A.I., Loukides S. et al. Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype. Respiratory Medicine. 2015; 109: 1404-1409. doi: 10.1016/j.rmed.2015.09.009Konstantellou E., Papaioannou A.I., Loukides S. et al. Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype. Respiratory Medicine. 2015; 109: 1404-1409. doi: 10.1016/j.rmed.2015.09.009Ciebiada M., Domagała M., Gorska-Ciebiada M., et al. Risk factors associated with irreversible airway obstruction in nonsmoking adult patients with severe asthma. Allergy and Asthma Proceedings. 2014; 35(5): 72-79. doi: 10.2500/aap.2014.35.3785Ciebiada M., Domagała M., Gorska-Ciebiada M., et al. Risk factors associated with irreversible airway obstruction in nonsmoking adult patients with severe asthma. Allergy and Asthma Proceedings. 2014; 35(5): 72-79. doi: 10.2500/aap.2014.35.3785Bennett G.H., Carpenter L., Hao W. et al. Risk factors and clinical outcomes associated with fixed airflow obstruction in older adults with asthma. Annals of Allergy, Asthma and Immunology. 2018; 120(2): 164-168. doi: 10.1016/j.anai.2017.10.004Bennett G.H., Carpenter L., Hao W. et al. Risk factors and clinical outcomes associated with fixed airflow obstruction in older adults with asthma. Annals of Allergy, Asthma and Immunology. 2018; 120(2): 164-168. doi: 10.1016/j.anai.2017.10.004Wang L., Gao S., Zhu W. et al. Risk factors for persistent airflow limitation: analysis of 306 patients with asthma. Pakistan Journal of Medical Sciences. 2014; 30(6): 1393-1397. doi: 10.12669/pjms.306.5363Wang L., Gao S., Zhu W. et al. Risk factors for persistent airflow limitation: analysis of 306 patients with asthma. Pakistan Journal of Medical Sciences. 2014; 30(6): 1393-1397. doi: 10.12669/pjms.306.5363Haddad A., Gaudet M., Plesa M. et al. Neutrophils from severe asthmatic patients induce epithelial to mesenchymal transition in healthy bronchial epithelial cells. Respiratory Research. 2019; 20(1): 234. doi: 10.1186/s12931-019-1186-8Haddad A., Gaudet M., Plesa M. et al. Neutrophils from severe asthmatic patients induce epithelial to mesenchymal transition in healthy bronchial epithelial cells. Respiratory Research. 2019; 20(1): 234. doi: 10.1186/s12931-019-1186-8Tashiro H., Shore S.A. Obesity and severe asthma. Allergology International. 2019; 68(2): 135-142. doi:10.1016/j.alit.2018.10.004.Tashiro H., Shore S.A. Obesity and severe asthma. Allergology International. 2019; 68(2): 135-142. doi:10.1016/j.alit.2018.10.004.Kim S., Lee C.H., Jin K.N. et al. Severe Asthma Phenotypes Classified by Site of Airway Involvement and Remodeling via Chest CT scan. J Investig Allergol Clin Immunol. 2018; 28(5): 312-320. doi: 10.18176/jiaci.0265.Kim S., Lee C.H., Jin K.N. et al. Severe Asthma Phenotypes Classified by Site of Airway Involvement and Remodeling via Chest CT scan. J Investig Allergol Clin Immunol. 2018; 28(5): 312-320. doi: 10.18176/jiaci.0265.Robinson D., Humbert M., Buhl R. et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical and Experimental Allergy. 2017; 47(2): 161–175. doi: 10.1111/cea.12880.Robinson D., Humbert M., Buhl R. et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical and Experimental Allergy. 2017; 47(2): 161–175. doi: 10.1111/cea.12880.Kuruvilla M.E., Lee F.E-H., Lee G.B. Understanding asthma Phenotypes, endotypes, and mechanisms of disease. Clinical Reviews in Allergy and Immunology. 2019; 56(2): 219–233. doi: 10.1007/s12016-018-8712-1Kuruvilla M.E., Lee F.E-H., Lee G.B. Understanding asthma Phenotypes, endotypes, and mechanisms of disease. Clinical Reviews in Allergy and Immunology. 2019; 56(2): 219–233. doi: 10.1007/s12016-018-8712-1Sze E., Bhalla A., Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020; 75(2): 311–325. doi: 10.1111/all.13985Sze E., Bhalla A., Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020; 75(2): 311–325. doi: 10.1111/all.13985Mogensen I., Alving K., Dahlen S-E. Et al. Fixed airflow obstruction relates to eosinophil activation in asthmatics. Clinical and Experimental Allergy. 2019; 49: 155–162. doi: 10.1111/cea.13302Mogensen I., Alving K., Dahlen S-E. Et al. Fixed airflow obstruction relates to eosinophil activation in asthmatics. Clinical and Experimental Allergy. 2019; 49: 155–162. doi: 10.1111/cea.13302Prosekova E.V., Turyanskaya A.I., Dolgopolov M.S. Interleukin-17 family in atopy and allergic diseases. Pacific Medical Journal. 2018; 2: 15–20. doi: 10.17238/PmJ1609-1175.2018.2.15–20 [In Russian].Просекова Е.В., Турянская А.И., Долгополов М.С. Семейство интерлейкина-17 при атопии и аллергических заболеваниях. Pacific Medical Journal. 2018; 2: 15–20. doi: 10.17238/PmJ1609- 1175.2018.2.15–20Tliba O., Panettieri R.A. Paucigranulocytic asthma: The uncoupling of airway obstruction from inflammation. Journal of Allergy and Clinical Immunology. 2019; 143(4): 1287–1294. doi: 10.1016/j.jaci.2018.06.008Tliba O., Panettieri R.A. Paucigranulocytic asthma: The uncoupling of airway obstruction from inflammation. Journal of Allergy and Clinical Immunology. 2019; 143(4): 1287–1294. doi: 10.1016/j.jaci.2018.06.008Rogliani P., Calzetta L., Matera M.G. et al. Severe asthma and biological therapy: when, which, and for whom. Pulmonary Therapy. 2020; 6(1): 47–66. doi: 10.1007/s41030-019-00109-1Rogliani P., Calzetta L., Matera M.G. et al. Severe asthma and biological therapy: when, which, and for whom. Pulmonary Therapy. 2020; 6(1): 47–66. doi: 10.1007/s41030-019-00109-1Pavord I.D., Afzalnia S., Menzies-Gow A., Heaney L.G. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clinical and Experimental Allergy. 2017; 47(2): 148-60. doi: 10.1111/cea.12881Pavord I.D., Afzalnia S., Menzies-Gow A., Heaney L.G. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clinical and Experimental Allergy. 2017; 47(2): 148-60. doi: 10.1111/cea.12881Pavord I.D., Afzalnia S., Menzies-Gow A., Heaney L.G. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clinical and Experimental Allergy. 2017; 47(2): 148-60. doi: 10.1111/cea.12881

The authors declare that there are no conflicts of interest present.